Pathology & Oncology Research最新文献

{"title":"Corrigendum: Blood, toil, and taxoteres: Biological determinants of treatment-induced ctDNA dynamics for interpreting tumor response.","authors":"Christopher T Boniface,&nbsp;Paul T Spellman","doi":"10.3389/pore.2023.1611133","DOIUrl":"https://doi.org/10.3389/pore.2023.1611133","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/pore.2022.1610103.].</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"29 ","pages":"1611133"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9314844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Case report: Potential predictive value of MMR/MSI status and PD-1 expression in immunotherapy for urothelial carcinoma.","authors":"Yu-Ting Ma,&nbsp;Yan Li,&nbsp;Li Yan,&nbsp;Fang Hua,&nbsp;Dong-Guan Wang,&nbsp;Guo-Ying Xu,&nbsp;Hong-Lan Yang,&nbsp;Ying-Jie Xue,&nbsp;Ye-Jun Qin,&nbsp;Dan Sha,&nbsp;Hao Ning,&nbsp;Miao-Qing Zhao,&nbsp;Zhi-Gang Yao","doi":"10.3389/pore.2023.1610989","DOIUrl":"https://doi.org/10.3389/pore.2023.1610989","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/pore.2022.1610638.].</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"29 ","pages":"1610989"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9924308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9282181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report: Urothelial carcinoma of the renal pelvis with trophoblastic differentiation: A rare case report and review of literature.","authors":"Zhuo Wang,&nbsp;Jinsui Wang,&nbsp;Wenwen Zhang,&nbsp;Daoying Wang,&nbsp;Xiaojun Wang,&nbsp;Xiaoqin Liang","doi":"10.3389/pore.2023.1610856","DOIUrl":"https://doi.org/10.3389/pore.2023.1610856","url":null,"abstract":"<p><p>We report a rare case of urothelial carcinoma (UC) of the renal pelvis with trophoblastic differentiation that occurred in a 55-year-old male patient. The patient presented with gross hematuria and paroxysmal lumbago pain 5 months ago. The enhanced computed tomography (CT) scan demonstrated a large space occupying lesion in the left kidney and multiple retroperitoneal lymph node enlargements. Histologically, high-grade infiltrating urothelial carcinoma (HGUC) contained giant cells which were positive for beta-human chorionic gonadotropin (β-hCG). Three weeks after resection, positron emission tomography and computed tomography (PET-CT) scan showed multiple nodules of metastasis in the left renal region, extensive systemic muscle, bone, lymph node, liver and bilateral lung metastases. The patient underwent bladder perfusion chemotherapy and gemcitabine combined with cisplatin chemotherapy regimens. This is the eighth documented case of UC of the renal pelvis with trophoblastic differentiation. Due to its rarity and extremely poor prognosis, it is important to clarify the characteristics of the disease and make an accurate and prompt diagnosis.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"29 ","pages":"1610856"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10781266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of the immune targets in tumor-infiltrating immunocytes of gestational trophoblastic neoplasia.","authors":"Hongyan Cheng,&nbsp;Liju Zong,&nbsp;Shuangni Yu,&nbsp;Jie Chen,&nbsp;Xirun Wan,&nbsp;Yang Xiang,&nbsp;Junjun Yang","doi":"10.3389/pore.2023.1610918","DOIUrl":"https://doi.org/10.3389/pore.2023.1610918","url":null,"abstract":"<p><p><b>Objectives:</b> To evaluate the expression of emerging immune targets in the tumor-infiltrating immunocytes (TIIs) of human gestational trophoblastic neoplasia (GTN) specimens, and to analyze the correlation between the expression patterns and prognosis of GTN patients. <b>Methods:</b> Between January 2008 and December 2017, patients who were diagnosed histologically with GTN were included in this study. The expression densities of LAG-3, TIM-3, GAL-9, PD-1, CD68, CD8, and FOXP3 in the TIIs were assessed independently by two pathologists blinded to clinical outcomes. The expression patterns and correlation with patient outcomes were analyzed to identify prognostic factors. <b>Results:</b> We identified 108 patients with GTN, including 67 with choriocarcinoma, 32 with placental site trophoblastic tumor (PSTT), and 9 with epithelioid trophoblastic tumor (ETT). Almost all GTN patients showed expression of GAL-9, TIM-3, and PD-1 in TIIs (100%, 92.6%, and 90.7%, respectively); LAG-3 was expressed in 77.8% of the samples. The expression densities of CD68 and GAL-9 were significantly higher in choriocarcinoma than that in PSTT and ETT. The TIM-3 expression density in choriocarcinoma was higher than that in PSTT. In addition, the expression density of LAG-3 in the TIIs of choriocarcinoma and PSTT was higher than that in ETT. There was no statistical difference in the expression pattern of PD-1 among different pathological subtypes. The positive expression of LAG-3 in tumor TIIs was a prognostic factor for disease recurrence, and patients with positive expression of LAG-3 in the TIIs had poorer disease-free survival (<i>p</i> = 0.026). <b>Conclusion:</b> Our study evaluated the expression of immune targets PD-1, TIM-3, LAG-3, and GAL-9 in the TIIs of GTN patients and found that they were widely expressed but not associated with patients' prognoses, excepting the positive expression of LAG-3 was a prognostic factor for disease recurrence.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"29 ","pages":"1610918"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10849698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"APOC1 predicts a worse prognosis for esophageal squamous cell carcinoma and is associated with tumor immune infiltration during tumorigenesis.","authors":"Xiying Cao,&nbsp;Bingqun Wu,&nbsp;Shaoming Guo,&nbsp;Weixiang Zhong,&nbsp;Shenyu Zhu,&nbsp;Zuxiong Zhang,&nbsp;Liang Gu,&nbsp;Hui Li","doi":"10.3389/pore.2023.1610976","DOIUrl":"https://doi.org/10.3389/pore.2023.1610976","url":null,"abstract":"<p><p><b>Background:</b> Esophageal carcinoma (ESCA), a common malignant tumor of the digestive tract with insidious onset, is a serious threat to human health. Despite multiple treatment modalities for patients with ESCA, the overall prognosis remains poor. Apolipoprotein C1 (APOC1) is involved in tumorigenesis as an inflammation-related molecule, and its role in esophageal cancer is still unknown. <b>Methods:</b> We downloaded documents and clinical data using The Cancer Genome Atlas (TCGA)and Gene Expression Omnibus (GEO) databases. We also conducted bioinformatics studies on the diagnostic value, prognostic value, and correlation between APOC1 and immune infiltrating cells in ESCA through STRING (https://cn.string-db.org/), the TISIDB (http://cis.hku.hk/TISIDB/) website, and various other analysis tools. <b>Results:</b> In patients with ESCA, APOC1 was significantly more highly expressed in tumor tissues than in normal tissues (<i>p</i> < 0.001). APOC1 could diagnose ESCA more accurately and determine the TNM stage and disease classification with high accuracy (area under the curve, AUC≥0.807). The results of the Kaplan-Meier curve analysis showed that APOC1 has prognostic value for esophageal squamous carcinoma (ESCC) (<i>p</i> = 0.043). Univariate analysis showed that high APOC1 expression in ESCC was significantly associated with worse overall survival (OS) (<i>p</i> = 0.043), and multivariate analysis shows that high APOC1 expression was an independent risk factor for the OS of patients with ESCC (<i>p</i> = 0.030). In addition, the GO (gene ontology)/KEGG (Kyoto encyclopedia of genes and genomes) analysis showed a concentration of gene enrichment in the regulation of T-cell activation, cornification, cytolysis, external side of the plasma membrane, MHC protein complex, MHC class II protein complex, serine-type peptidase activity, serine-type endopeptidase activity, <i>Staphylococcus aureus</i> infection, antigen processing and presentation, and graft-versus-host disease (all <i>p</i> < 0.001). GSEA (gene set enrichment analysis) showed that enrichment pathways such as immunoregulatory-interactions between a lymphoid and non-lymphoid cell (NES = 1.493, p. adj = 0.023, FDR = 0.017) and FCERI-mediated NF-KB activation (NES = 1.437, p. adj = 0.023, FDR = 0.017) were significantly enriched in APOC1-related phenotypes. In addition, APOC1 was significantly associated with tumor immune infiltrating cells and immune chemokines. <b>Conclusion:</b> APOC1 can be used as a prognostic biomarker for esophageal cancer. Furthermore, as a novel prognostic marker for patients with ESCC, it may have potential value for further investigation regarding the diagnosis and treatment of this group of patients.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"29 ","pages":"1610976"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9193627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: <i>In vivo</i> and <i>in vitro</i> models for research in pathology.","authors":"Songwen Tan,&nbsp;Peter Nemeth","doi":"10.3389/pore.2023.1611196","DOIUrl":"https://doi.org/10.3389/pore.2023.1611196","url":null,"abstract":"JAK-STAT signaling pathway and apoptosis in rats. The study highlights the importance of investigating the baselines at different time points when assessing the therapeutic effect of drugs, as the pathological changes and protein expression can vary over time. The results suggest that JAK-STAT signaling pathway activation plays a vital role in RIRI and that apoptosis is","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"29 ","pages":"1611196"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9385445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients.","authors":"Adi Horesh,&nbsp;Rena Pollack,&nbsp;Hovav Nechushtan,&nbsp;Rivka Dresner-Pollak,&nbsp;Tzahi Neuman","doi":"10.3389/pore.2023.1610951","DOIUrl":"https://doi.org/10.3389/pore.2023.1610951","url":null,"abstract":"<p><p><b>Background:</b> Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), however are frequently associated with thyroid immune-related adverse events (IRAEs). We investigated the association between patient characteristics, tumor PD-L1 expression and molecular profile with the development of thyroid IRAEs in NSCLC patients. <b>Methods:</b> Single center, retrospective study including 107 NSCLC patients treated with PD-1/PD-L1 inhibitors from April 2016 to July 2020. All patients were euthyroid at baseline with at least two TSH measurements post-treatment initiation. The primary outcome was the difference in tumor PD-L1 expression in patients who developed any thyroid IRAEs versus those who remained euthyroid. Additional outcomes included development of overt thyroid dysfunction, the association of specific molecular alterations with thyroid IRAEs, and onset of thyroid IRAEs as a function of tumor PD-L1 expression. <b>Results:</b> Overall, 37 (34.6%) patients developed any thyroid dysfunction and 18 (16.8%) developed overt thyroid dysfunction. Tumor PD-L1 staining intensity was not associated with thyroid IRAEs. TP53 mutation was less likely to be associated with any thyroid dysfunction (<i>p</i> < 0.05) and no association was found between EGFR, ROS, ALK or KRAS mutations. There was no association between PD-L1 expression and time to develop thyroid IRAEs. <b>Conclusion:</b> PD-L1 expression is not associated with the development of thyroid dysfunction in advanced NSCLC patients treated with ICIs, suggesting that thyroid IRAEs are unrelated to tumor PD-L1 expression.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"29 ","pages":"1610951"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9779782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a prognostic nomogram for rectal cancer patients who underwent surgical resection.","authors":"Bochao Zhao,&nbsp;Jingchao Wang,&nbsp;Zhicheng Ma,&nbsp;Haikun Ye,&nbsp;Tao Yang,&nbsp;Kewei Meng","doi":"10.3389/pore.2023.1611014","DOIUrl":"https://doi.org/10.3389/pore.2023.1611014","url":null,"abstract":"<p><p><b>Objective:</b> The purpose of this study was to develop and validate a nomogram model for the prediction of survival outcome in rectal cancer patients who underwent surgical resection. <b>Methods:</b> A total of 9,919 consecutive patients were retrospectively identified using the Surveillance, Epidemiology, and End Results (SEER) database. Significant prognostic factors were determined by the univariate and multivariate Cox analysis. The nomogram model for the prediction of cancer-specific survival (CSS) in rectal cancer patients were developed based on these prognostic variables, and its predictive power was assessed by the concordance index (C-index). Calibration curves were plotted to evaluate the associations between predicted probabilities and actual observations. The internal and external cohort were used to further validate the predictive performance of the prognostic nomogram. <b>Results:</b> All patients from the SEER database were randomly split into a training cohort (<i>n</i> = 6,944) and an internal validation cohort (<i>n</i> = 2,975). The baseline characteristics of two cohorts was comparable. Independent prognostic factors were identified as age, pT stage, lymph node metastasis, serum CEA level, tumor size, differentiation type, perineural invasion, circumferential resection margin involvement and inadequate lymph node yield. In the training cohort, the C-index of the nomogram was 0.719 (95% CI: 0.696-0.742), which was significantly higher than that of the TNM staging system (C-index: 0.606, 95% CI: 0.583-0.629). The nomogram had a C-index of 0.726 (95% CI: 0.691-0.761) for the internal validation cohort, indicating a good predictive power. In addition, an independent cohort composed of 202 rectal cancer patients from our institution were enrolled as the external validation. Compared with the TNM staging system (C-index: 0.573, 95% CI: 0.492-0.654), the prognostic nomogram still showed a better predictive performance, with the C-index of 0.704 (95% CI: 0.626-0.782). Calibration plots showed a good consistency between predicted probability and the actual observation in the training and two validation cohorts. <b>Conclusion:</b> The nomogram showed an excellent predictive ability for survival outcome of rectal cancer patients, and it might provide an accurate prognostic stratification and help clinicians determine individualized treatment strategies.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"29 ","pages":"1611014"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9429407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Wide-field optical coherence tomography for microstructural analysis of key tissue types: a proof-of-concept evaluation.","authors":"Beryl Rabindran,&nbsp;Adriana D Corben","doi":"10.3389/pore.2023.1611167","DOIUrl":"https://doi.org/10.3389/pore.2023.1611167","url":null,"abstract":"<p><p><b>Introduction:</b> The presence of positive margins following tumor resection is a frequent cause of re-excision surgery. Nondestructive, real-time intraoperative histopathological imaging methods may improve margin status assessment at the time of surgery; optical coherence tomography (OCT) has been identified as a potential solution but has not been tested with the most common tissue types in surgical oncology using a single, standardized platform. <b>Methods:</b> This was a proof-of-concept evaluation of a novel device that employs wide-field OCT (WF-OCT; OTIS 2.0 System) to image tissue specimens. Various cadaveric tissues were obtained from a single autopsy and were imaged with WF-OCT then processed for permanent histology. The quality and resolution of the WF-OCT images were evaluated and compared to histology and with images in previous literature. <b>Results:</b> A total of 30 specimens were collected and tissue-specific microarchitecture consistent with previous literature were identified on both WF-OCT images and histology slides for all specimens, and corresponding sections were correlated. Application of vacuum pressure during scanning did not affect specimen integrity. On average, specimens were scanned at a speed of 10.3 s/cm² with approximately three features observed per tissue type. <b>Conclusion:</b> The WF-OCT images captured in this study displayed the key features of the most common human tissue types encountered in surgical oncology with utility comparable to histology, confirming the utility of an FDA-cleared imaging platform. With further study, WF-OCT may have the potential to bridge the gap between the immediate information needs of the operating room and the longer timeline inherent to histology workflow.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"29 ","pages":"1611167"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9919476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer.","authors":"Guohu Han,&nbsp;Changchun Sun,&nbsp;Lihua Cui,&nbsp;Yufeng Huang,&nbsp;Lijiang Yu,&nbsp;Shenzha Liu,&nbsp;Min Tao","doi":"10.3389/pore.2023.1611114","DOIUrl":"https://doi.org/10.3389/pore.2023.1611114","url":null,"abstract":"<p><p><b>Aim:</b> To observe the efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment for patients with human epidermal growth factor receptor 2 (HER-2) negative advanced gastric cancer. <b>Methods:</b> 80 eligible patients with HER-2 negative advanced gastric cancer admitted to Jingjiang People's Hospital Affiliated with Yangzhou University-from March 2021 to March 2022 were selected, and they were divided into the control group (<i>n</i> = 40, apatinib) and experimental group (<i>n</i> = 40, apatinib plus deep hyperthermia) on the basis of random number table method. The levels of serum carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199), and vascular endothelial growth factor (VEGF) were monitored, and the efficacy of the two groups was analyzed by referring to Karnofsky performance status (KPS), overall survival (OS) and disease control rate (DCR) before and after treatment. <b>Results:</b> The levels of CEA, CA199, and VEGF in both groups were lower after treatment than before (<i>p</i> < 0.05), and lower (CEA: 8.85 ± 1.36 vs. 12.87 ± 1.23, CA199: 34.19 ± 4.68 vs. 50.11 ± 5.73, VEGF: 124.8 ± 18.03 vs. 205.9 ± 19.91) in the experimental group than in the control group (<i>p</i> < 0.05). The DCR and KPS of the patients in the experimental group were significantly higher (DCR: 62.50% vs. 40.00%; KPS: 83.25 ± 1.15 vs. 76.25 ± 1.17) than in the control group (<i>p</i> < 0.05). In survival analysis, patients with control group had shorter OS than the experimental group. (median 5.65 vs. 6.50 months; hazard ratio [HR], 1.63 [95% confidence interval (CI) 1.02-2.60], <i>p</i> = 0.0396). <b>Conclusion:</b> The application of low-dose apatinib plus deep hyperthermia for patients with HER-2 negative gastric cancer who failed second-line treatment should be a promising option.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"29 ","pages":"1611114"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9847142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}